Health Equity and Clinical Research

  Sustainable Clinical Trials: The Pharmaceutical Industry's Path Forward Bridging Healthcare Innovation with Environmental Responsibility "We won't have a society if we destroy the environment."  - Margaret Mead The pharmaceutical industry plays a pivotal role in global health, spearheading the development of novel drugs and treatments that enhance and save lives. However, this paramount role also comes with its share of environmental consequences. Clinical trials, the foundational process of validating new drugs and treatments, significantly contribute to this ecological footprint. Environmental Impact of Clinical Trials Clinical trials conducted in 2020 generated approximately 2.3 million tons of waste 1 , including unused drugs, packaging materials, and medical devices. Unfortunately, much of this waste is in landfills, polluting our soil and water. Additionally, clinical trials require significant energy and leave a large carbon footprint due to participant trans...

The Transformative Power of Clinical Trial Referrals in Non-Academic Practices "Alone, we can do so little; together, we can do so much."  - Helen Keller In the rapidly evolving healthcare landscape, the referral of patients from non-academic medical practices to clinical trials emerges as a potent collaborative strategy. The benefits of this referral mechanism ripple beyond individual interactions, impacting all stakeholders positively – the referring physician, the patient, and the Principal Investigator (P.I.) and Sub-Investigator (Sub I). Organizations facilitating this process and the pharmaceutical companies sponsoring these trials play instrumental roles in this ecosystem. For the Referring Physician and Patients Referring patients to clinical trials brings many advantages to physicians outside academic medical centers. It allows them to provide their patients' access to potentially groundbreaking treatments and a unique opportunity to stay updated with the latest ...

    Diversity in Clinical Trials: A Strategic and Economic Game-Changer? Editorial by Brian J. Stowell "We are not makers of history. We are made by history."  - Dr. Martin Luther King Jr. Introduction In the evolving landscape of clinical trials, supplier and patient diversity programs are no longer seen as merely ethical or compliance requirements—they are strategic imperatives. They enhance the overall efficacy of clinical trials, influence competitive differentiation, and contribute to economic growth. This article will unravel how these diversity programs can provide a strategic advantage, deliver measurable economic benefits, and, most importantly, improve health outcomes for diverse patient populations. Supplier Diversity Programs Supplier diversity programs encourage the inclusion of diverse suppliers, such as minority-owned, women-owned, and small businesses, in the procurement process for clinical trials. Not only does this lead to a more innovative and resilien...